This represents a 12 percent drop in the number of new listings from a year ago, Deloitte said. Ninety-eight percent of the proceeds are from mainland companies, including 16 new listings that raised at least HK$7.8 billion each. Six of these were secondary listings. In 2021, Hong Kong is expected to have about 120-130 IPOs raising more than HK$400 billion from listings such as life sciences and biotech companies. Deloitte forecasts that more than 10 secondary new listings in Hong Kong will raise proceeds of over HK$100 billion.

Source: The Standard December 16, 2020 07:07 UTC